ConcertAI Integrates ASCO Guidelines into AI Precision Suite

ConcertAI has integrated the American Society of Clinical Oncology (ASCO) Guidelines into its AI-driven Precision Suite and CancerLinQ SmartLinQ solutions, announced in a press release. This integration, powered by the CARAai platform, aims to provide guideline-concordant care recommendations to medical oncologists within the CancerLinQ Network and biopharma researchers using Precision Explorer and Trials.

The integration allows biopharma researchers to assess guideline-concordant care and outcomes, while oncologists using SmartLinQ solutions will receive ASCO Guideline-concordant recommendations for patient treatment options. This enhancement is part of ConcertAI's ongoing efforts to optimize patient outcomes by providing comprehensive treatment options.

The ASCO Guidelines will be available within these solutions by June 30th, facilitating the assessment of guideline-concordant care across various settings and informing clinical trial design. The CancerLinQ SmartLinQ deployment of these guidelines will be showcased at the 2025 ASCO Annual Meeting in Chicago.